Akebia Therapeutics (AKBA) Non Operating Income (2013 - 2026)
Akebia Therapeutics (AKBA) reported Non Operating Income of $3000.0 for Q1 2026, down 98.59% year-over-year from $213000.0 in Q1 2025, and up 102.56% quarter-over-quarter from -$117000.0 in Q4 2025.
Akebia Therapeutics (AKBA) Non Operating Income (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 14 years of Non Operating Income data on file, last reported at $3000.0 in Q1 2026.
- Non Operating Income for Q1 2026 came in at $3000.0, down 98.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$152000.0 (down 171.7% YoY), and the FY2025 annual result was $58000.0, down 38.3% from the prior year.
- Non Operating Income climbed to $3000.0 in Q1 2026 per AKBA's latest filing, from -$117000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $1.2 million in Q3 2022 and troughed at -$117000.0 in Q4 2025.
- A 5-year average of $246352.9 and a median of $55000.0 in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income jumped 604.35% in 2022, then slumped 312.73% in 2025.
- A 5-year view of Non Operating Income shows it stood at $434000.0 in 2022, then surged by 51.61% to $658000.0 in 2023, then slumped by 91.64% to $55000.0 in 2024, then sank by 312.73% to -$117000.0 in 2025, then surged by 102.56% to $3000.0 in 2026.
- Business Quant data shows AKBA's Non Operating Income at $3000.0 in Q1 2026, -$117000.0 in Q4 2025, and -$10000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -216.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 20.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -7.50 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -504,111.66 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 53.40 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -13.65 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -23.23 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 5.71 Mn |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | -117,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Mar 31, 2025 | 213,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | -17,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Mar 31, 2024 | 95,000.00 |
| Dec 31, 2023 | 658,000.00 |
| Sep 30, 2023 | -43,000.00 |
| Jun 30, 2023 | -10,000.00 |
| Mar 31, 2023 | 282,000.00 |
| Dec 31, 2022 | 434,000.00 |
| Sep 30, 2022 | 1.17 Mn |
| Jun 30, 2022 | 411,000.00 |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 560,000.00 |
| Sep 30, 2021 | 427,000.00 |
| Jun 30, 2021 | 1.27 Mn |